Abstract:The farnesoid-x-receptor (FXR) and the G protein bile acid activated receptor (GPBAR)1 are two bile acid activated receptors highly expressed in entero-hepatic, immune, adipose and cardiovascular tissues. FXR and GPBAR1 are clinically validated targets in the treatment of metabolic disorders and FXR agonists are currently trialled in patients with non-alcoholic steato-hepatitis (NASH). Results of these trials, however, have raised concerns over safety and efficacy of selective FXR ligands suggesting that the development of novel agent designed to impact on multiple targets might have utility in the treatment of complex, multigenic, disorders. Harnessing on FXR and GPBAR1 agonists, several novel hybrid molecules have been developed, including dual FXR and GPBAR1 agonists and antagonists, while exploiting the flexibility of FXR agonists toward other nuclear receptors, dual FXR and peroxisome proliferators-activated receptors (PPARs) and liver-X-receptors (LXRs) and Pregnane-X-receptor (PXR) agonists have been reported. In addition, modifications of FXR agonists has led to the discovery of dual FXR agonists and fatty acid binding protein (FABP)1 and Leukotriene B4 hydrolase (LTB4H) inhibitors. The GPBAR1 binding site has also proven flexible to accommodate hybrid molecules functioning as GPBAR1 agonist and cysteinyl leukotriene receptor (CYSLTR)1 antagonists, as well as dual GPBAR1 agonists and retinoid-related orphan receptor (ROR)γt antagonists, dual GPBAR1 agonist and LXR antagonists and dual GPBAR1 agonists endowed with inhibitory activity on dipeptidyl peptidase 4 (DPP4). In this review we have revised the current landscape of FXR and GPBAR1 based hybrid agents focusing on their utility in the treatment of metabolic associated liver disorders.

The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer

Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities

Development of bile acid activated receptors hybrid molecules for the treatment of inflammatory and metabolic disorders

FXR: structures, biology, and drug development for NASH and fibrosis diseases

The pathophysiological function of non-gastrointestinal farnesoid X receptor.

Intestinal Farnesoid X Receptor Signaling Modulates Metabolic Disease

The regulation of tissue-specific farnesoid X receptor on genes and diseases involved in bile acid homeostasis

[Progress in the Role of Farnesoid X Receptor in Metabolic Regulation and Tumor Cell Proliferation].

Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer

Discovery of farnesoid X receptor and its role in bile acid metabolism

Pleiotropic roles of FXR in liver and colorectal cancers

Update on FXR Biology: Promising Therapeutic Target?

Bile Acids and the Gut Liver Axis

Farnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls Hepatic Lipid Metabolism

FXR Modulators for Enterohepatic and Metabolic Diseases.

Bile acid nuclear receptor FXR and digestive system diseases

Intestinal microbiota-farnesoid X receptor axis in metabolic diseases

FXR agonists for colorectal and liver cancers, as a stand-alone or in combination therapy

Potential of Intestine-Selective FXR Modulation for Treatment of Metabolic Disease

Farnesoid X receptor mediates macrophage-intrinsic responses to suppress colitis-induced colon cancer progression

Farnesoid X receptor gene polymorphisms and metabolic disease